Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016 by Beeton, Michael L. et al.
 
 
Title: Mycoplasma pneumoniae infections across 
Europe and Israel (2011-2016).  
Michael L. Beeton1, Xu-Sheng Zhang2, Søren A. Uldum3, Cécile Bébéar4, Roger Dumke5, Karolina 
Gullsby6, Margareta Ieven7, Katherine Loens7, Ran Nir-Paz8, Sabine Pereyre4, O. Brad Spiller9, Victoria 
J.  Chalker2 and the ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) 
Mycoplasma pneumoniae sub-group10. 
1. Department of Biomedical Sciences, Cardiff Metropolitan University, Cardiff, United Kingdom. 
2. Public Health England, London, United Kingdom. 
3. Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark. 
4. USC-EA 3671, Mycoplasmal and chlamydial infections in humans, University of Bordeaux, INRA, 
Bordeaux, France 
5. TU Dresden, Dresden, Germany. 
6. Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden.    
7. Universitair Ziekenhuis Antwerpen, Edegem, Belgium. 
8. Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical 
Center, Jerusalem, Israel. 
9. Department of Medical Microbiology and Infectious Disease, Cardiff University, Cardiff, United 
Kingdom 
10ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma 
pneumoniae sub-group: 
• European Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) committee: 
Victoria Chalker (Public Health England, UK), Roger Dumke (Dresden, Germany), Brad Spiller 
(Cardiff University, UK), Margareta Ieven (University Hospital Antwerp, Belgium), Katherine 
Loens (University Hospital Antwerp, Belgium), Ran Nir-Paz (Hadassah-Hebrew University 
Medical Center, Israel), Cécile Bébéar (University Bordeaux, France), Sabine Pereyre 
(University Bordeaux, France), Søren Uldum (Statens Serum Institut, Denmark), Michael 
Beeton (Cardiff Metropolitan University, UK). 
• Belgium: Katherine Loens, Margareta Ieven, (National Reference Centre for Respiratory 
Pathogens, University Hospital Antwerp, Antwerp, Belgium), Nathalie Bossuyt 
(Epidemiologie van Infectieziekten, Sciensano, Brussels, Belgium) Katrien Lagrou (National 
Reference Centre for Respiratory Pathogens, University Hospital Leuven, Leuven, Belgium) 
• Cyprus: George Mitis (Immunology Department, Nicosia General Hospital),  Maria Koliou 
(Department of Paediatrics, Archbishop Makarios III Hospital)  
• Czech Republic: Martina Havlickova and Jan Kyncl (National Institute of Public Health)  




• France: Cécile Bébéar, Sabine Pereyre (USC-EA 3671 Mycoplasmal and Chlamydial Infections 
in Humans, University of Bordeaux, INRA, Bordeaux, France) 
• Germany: Roger Dumke (Dresden), Colin Rae MacKenzie (Institute of Medical Microbiology 
and Hospital Hygiene, Heinrich-Heine-University,  Germany) 
• Greece: Helena Maltezou, Theano Georgakopoulou (Hellenic Centre for Disease Control and 
Prevention, Athens); Evangelina Petridou, Kirkira Banou (Aghia Sophia Children Hospital, 
Athens)  
• Hungary: Eszter Balla (Department of Reference Laboratories, National Public Health Center, 
Budapest)  
• Ireland: Jeff Connell, Zoe Yandle, Joanne Moran (University College Dublin, National Virus 
Reference Laboratory), Karen Burns (Health Protection Surveillance Centre, Dublin)  
• Israel: Ran Nir Paz, Ayelet Michael-Gayego, Allon Moses (Department of Clinical 
Microbiology and infectious Diseases, Hadassah-Hebrew University Medical Centre) 
• Malta: Tanya Melillo Fenech (Ministry of Health) 
• The Netherlands:  Marit de Lange, RIVM - Centre Infectious Disease Control Netherlands  
• Norway: Norway: Hans Blystad and Gabriel Ånestad, Didrik F. Vestrheim (Norwegian 
Institute of Public Health)   
• Portugal: Filipe Froes (Hospital Pulido Valente and General Directorate of Health Consultant 
for Pneumology)  
• Slovenia: Darja Kese (Institute of Microbiology and Immunology, University of Ljubljana) and 
Maja Socan (National Institute of Public Health)  
• Spain: Rosa Cano Portero (National Center for Epidemiology, Instituto de Salud Carlos III. 
CIBERESP), Sara Santos Sanz and Berta Suárez Rodríguez (Coordination for Alerts and Public 
Health Emergencies, Directorate General of Public Health, Ministry of Health, Social Affairs 
and Equality  
• Sweden: Anders Ternhag (Karolinska University Hospital and Public Health Agency of 
Sweden), Christian Giske (Karolinska University Hospital), Karin Tegmark Wisell (Public 
Health Agency of Sweden), Karolina Gullsby (Centre for Research and Development, Uppsala 
University/Region Gävleborg, Gävle, Sweden) 
• United Kingdom: Diogo Pereira Marques, Arlene Reynolds, Jim McMenamin and Beatrix von 
Wissmann, Eleanor Anderson (Health Protection Scotland, Glasgow, UK), Victoria Chalker 
(Public Health England, Colindale) 
 
Corresponding author: Dr Victoria Chalker 
Corresponding author email: vicki.chalker@phe.gov.uk  
 
Keywords: Mycoplasma pneumoniae; epidemiology; diagnostics; surveillance  
Conflict of interest: None to declare 







Mycoplasma pneumoniae is a leading cause of community acquired pneumonia with large epidemics 
occurring every 4 to 7 years. Infections are predominantly seen among paediatric populations. 
Aim 
To determine the diagnostic methods used to detect M. pneumoniae, the seasonality of detections, 
identification of epidemics, macrolide resistance data availability, patient age demographics for 
positive detections and the effect of geographical location on timing of epidemics.   
Methods 
A retrospective questionnaire was sent out to 18 countries across Europe and Israel requesting details 
on the number of M. pneumoniae positive samples from January 2011 to April 2016.  Information 
requested included: methods of detection, date of detection, availability of macrolide resistance data 
and number of detections stratified by age group.  The Moving Epidemic Method was used to 
determine epidemic periods across the countries for the five periods under investigation and effect of 
country latitude 
Results 
12/18 countries supplied data on M. pneumoniae infections accounting for 95,666 positive samples. 
Few laboratories have initiated routine macrolide resistance testing since 2013. Between 2011 – 2016 
three epidemics were identified during 2011/12, 2014/15 and 2015/16. Three patterns emerged from 
the distribution of patient ages for M. pneumoniae positive samples. During epidemic years an 
association between country latitude and week number in which epidemic periods began was noted.   
Conclusions 
This study represents the largest multi-national epidemiological analysis of M. pneumoniae data. 
Association between epidemics and latitude was observed. Differences were noted in age distribution 




Mycoplasma pneumoniae is a major cause of respiratory infection in humans with macrolide 
antibiotics, such as azithromycin, used as the first-line treatment in many countries. The bacterium is 
transmitted from person to-person by respiratory droplets with the incubation period ranging from 4 
days to 3 weeks (1). Prudent use of antibiotics has been urged for all cases of M. pneumoniae infection 
because of worldwide reports of macrolide resistance which have been reported as ranging from 0.2 
% in Sweden to greater than  90% in China (2-5). M. pneumoniae infections show seasonal variation.  
In temperate climates the number of infections peak during the latter months of the years with 
epidemic periods on average every 4 to 7 years (6-8). The most recent survey in 2012 by Lenglet et al. 
indicated that some countries in the European Union and European Economic Area experienced an 
increase in M. pneumoniae cases in 2011 whereas others did not, indicating a universal geographic 
increase had not occurred (5). Little is understood about transmission of M. pneumoniae within 
populations and several factors have been postulated to account for dynamics including immunity 
level of the population, the bacterial population based on the P1 adhesin type, age and increased 
mixing of children in academic and nursery settings.  
Testing methodologies include nucleic acid amplification test (NAAT), serology and culture with 
varying sensitivities and specificities. There is no international standard material for quality control 
detection in assays, although external quality control schema exist for some methodologies (NAAT). 
There are no internationally defined guidelines on the requirements for surveillance of M. 
pneumoniae, macrolide resistance testing and surveillance, reference system structure, routine 
testing and bacterial strain discrimination. However, a few countries such as France and the USA have 
introduced surveillance for specific regions and national surveillance is seen in countries such as 
Denmark and Japan which have maintained an active surveillance system for this pathogen for some 
time (9). Due Therefore, the laboratory confirmed cases and surveillance data regarding the number 
of cases and the reported cases of macrolide resistance are likely to be underestimates. This is further 
confounded due to both the challenge in diagnosis and the fact that an undefined proportion of 
patients will have mild disease or may be carriers within community settings, without active testing 
to confirm the infection. Further underestimation is likely to occur from patients receiving empirical 
treatment without diagnostics to confirm infection.  
In response to an increase in infection seen in several countries in 2016, the ESCMID Study Group for 
Mycoplasma Infections (ESGMI), which is now recognised as the ESCMID Study Group for Mycoplasma 
and Chlamydia Infections (ESGMAC), established this study (10, 11). The purpose of the study was to 
determine case number per age group, concurrence of epidemic and annual peaks across geographies, 
 
 
to gain a greater understanding of testing and surveillance systems in use for M. pneumoniae and to 
establish the extent of macrolide resistance testing, whilst establishing if macrolide resistance testing 
was in place. ESGMI conducted an email based survey of ESGMI members in countries in Europe and 
Israel to describe the existing laboratory confirmed case data for M. pneumoniae infection by age 
group from 03-01-2011 to 24-04-2016. Of the 18 countries that participated in the survey, 12 reported 





Study type, data collection and analysis 
A retrospective email survey based study was undertaken of laboratory confirmed documented 
detections of M. pneumoniae from national laboratory and surveillance institutions or, if not available, 
other regional laboratory and surveillance institutions. Countries invited to participate in the study 
were either active members of ESGMI or authors listed in the previous study by Lenglet et al (5). 
Participants were invited to join the study and provide the number of detections confirmed by nucleic 
acid amplification test (NAAT), serology, culture and total overall between weeks commencing 03-01-
2011 to 24-04-2016 (positive results and if available negative results were also collated).   
Additional information was requested including whether countries were actively monitoring 
macrolide resistance. Data from each participating country was collated and aggregated to give total 
number of detections per age group and 4 weekly moving averages of detections per country and 
overall where possible. We did not request data on the gender of patient from which the detections 
were made. Total weekly data were further subcategorised by age group (0-4y, 5-9y, 10-14y, 15-24y, 
25-44y, 45-64y, 65+ or unknown). 
Case definition 
Cases of M. pneumoniae infection were defined by local practice. Due to local variation this study 
collated information on M. pneumoniae detections, not cases. 
De-duplication and exclusion criteria. 
Due to the heterogeneous nature of M. pneumoniae data collection from each country specific study-
wide de-duplication criteria would not have been feasible; therefore, participants were asked to detail 
if data with duplicate samples from the same patient (eg. with NAAT and serology) was included as a 
single category and if possible to include as serology. Specific exclusion criteria were also not set for 
similar reasons stated above.  Responses for de-duplication and exclusion criteria are listed in 
supplementary data (S1).  
Characteristics of epidemics between January 2011 to April 2016. 
To determine the characteristic properties of epidemics across the 12 countries which provided data 
on M. pneumoniae positivity the Moving Epidemic Method (MEM) was used. (12)  An epidemic slope 
threshold of 2% was chosen and used to determine the pre-epidemic period, epidemic period and 
post-epidemic period for the 5 periods which coincide with annual peaks spanning week 19 of the first 
 
 
year through to week 18 of the following year. These data were used to calculate the duration of 
epidemic for each country as well as the percentage of positive samples which were identified within 
this period. Data generated from the MEM model, such as week number in which epidemics began, 
was used to correlate the onset of epidemics with the geographical location of each country. Statistical 
analysis for generating p-values and calculation of r2 were performed with GraphPad Prism 5. 
Ethics statement 
This study involved collation of surveillance data for epidemiological analysis and all data was 
retrospective and analysed for public health interest. Ethical approval was not required and no patient 





Data availability and diagnostic methods used for detection of M. pneumoniae across Europe and 
Israel  
In the period between 3rd January 2011 and 24th April 2016 a total of 95,666 detections of M. 
pneumoniae were confirmed from 12 participating countries across Europe and Israel. Of the 18 
countries approached, 12 provided information regarding M. pneumoniae.  The method of M. 
pneumoniae detection varied between the 12 countries (Table 1).  Two countries (Denmark and Israel) 
reported exclusively NAAT use, two countries (Greece and Ireland) reported serology exclusively, five 
countries (Great Britain, Germany, Hungary, Norway and Sweden) used a combination of NAAT and 
serology, one country (Slovenia) used NAAT in combination with culture, two countries (Belgium and 




































Macrolide resistance monitoring 
 
Performed Number of 
positive 
detections 
Performed Number of 
positive 
detections 
Performed Number of 
positive 
detections 
Belgium Yes 894 Yes 49 Yes  12,047 21,094* No data 
available 
N/A Only monitored when samples test 
positive at the National Reference 
Centre. No testing in Sentinel 
Laboratories 
Denmark Yes 20,081 No N/A No N/A 20,081 264,770  7.0 % No routine surveillance system in 
place.  From 2010/11, 2011/12 and 
2015/16 periods 809 samples were 
examined identifying 13 macrolide 
resistance associated mutations 
(1.5%). Samples are investigated 
on request form physicians 
France Yes 92 Yes 53** Yes 298 390 7,463 5.0 % Performed on all clinical 
specimens detected as M. 
pneumoniae-positive by NAAT 
since 2013 [9] 
Germany Yes 127 No N/A Yes 316 443 10,143 4.2 % No comment 
Great 
Britain 
Yes 385 No N/A Yes 5,263 5,648 No data 
available 
N/A No national system 
All positives samples referred to 
PHE are tested. 
Greece No N/A No N/A Yes 140 140 1,498 8.5 % No comment 
Hungary Yes 17 No N/A Yes 1,117 1,134 6,109 15.7 % No comment 
Ireland No N/A No N/A Yes 535 535 2,853 15.8 % No comment 
Israel Yes 848 No N/A No N/A 848 5,309 13.8 % No active monitoring 
Norway Yes 13,980 No N/A Yes 10,678 24,658 No data 
available 
N/A No comment 
Slovenia Yes 1,172 Yes 827 No N/A 1,172 8,872 11.7 % Only on request from physician 
Sweden Yes 9,499 No N/A Yes 10,024 19,523 169,501 10.3 % No active monitoring 
Sum of 
columns 
N/A 47,095 N/A 876 N/A 40,418 95,666 476,518 N/A  
*Method of detection not known for sentinel laboratories ** Not included in the overall total for the purpose of deduplication. N/A = not 




The greatest number of positive samples were reported using NAAT (47,095, 49%) followed by 
serology (40,418, 42%). Only 876 (1%) samples were reported positive by culture and 7,277 (8%) of 
tests were not specified.  Norway contributed the greatest number of M. pneumoniae positive 
detections to the total figure (24,658, 26%) and Greece the lowest (140, 0.1%). De-duplication data 
was determined at a country level (S1). 
 
Macrolide resistance data availability 
With regards to active monitoring of macrolide resistance, five countries did not comment, Belgium 
noted that monitoring was only carried out on positive samples identified in the National Reference 
Laboratory, but not within sentinel laboratories, Slovenia noted that macrolide resistance 
determination was carried out only on request by the physician, Denmark investigated NAAT positive 
samples from three recent M. pneumoniae epidemic periods and found low level (1.5%) of macrolide 
resistance, and samples are investigated on request from physicians, France initiated a systematic 
monitoring on all NAAT-positive clinical specimens in 2013 using an in-house published method (13). 
In 2017, England and Wales introduced monitoring of all positive NAAT samples referred to the 
national reference laboratory. Two countries stated that no monitoring for resistance was in place 
(Table 1). 
 
Total number of detections and seasonality 
The distribution and seasonality of the 95,666 detections from the twelve countries across the study 
period was determined.  To account for weekly bias in reporting, data was converted to four weekly 
moving averages. The greatest number of positive samples from the 4 weekly moving averages data 
was identified as 1758.5 positive detections during week 48 of 2011.  
Detection of M. pneumoniae by NAAT (Figure 1b) correlated with the overall detections seen in Figure 
1a.  Detection of M. pneumoniae by culture gave the lowest number of positive samples accounting 
for 1% of the total positive samples. Detection using serology was the second most common method 
for detecting M. pneumoniae positive patients (Figure 1c).  The 4 week rolling average for detection 
by culture (Figure 1d) was less than five positive samples for all reporting weeks with exception of 
Slovenia in the 2015 season where a maximum average of 51.8 positive samples were identified.  
 
 
Identification of epidemic periods using the Moving Epidemic Model. 
Analysis of detections during the annual periods was carried out using the Moving Epidemic Model 
(Figure 2). For the five annual periods described we noted 35747; 11089; 8510; 15312; 19439 
detections for the periods 2011/12, 2012/13, 2013/14, 2014/15 and 2015/16, respectively. Three 
epidemics were detected between 2011/12, 2014/15, and 2015/16 in which 67%, 59% and 68% of 
each period’s detections were identified during the calculated epidemic period, respectively. 
Epidemics had longer duration (19, 21 and 23 weeks, respectively) compared to numbers observed 
during annual seasonal peaks of infection (non-epidemic periods) 2012/13 (13 weeks with 30% of total 
detections) and 2013/2014 (15 weeks with  35% of total detections). For countries which provided the 
total number of negative samples the percentage of positive samples identified during the pre-
epidemic period, epidemic period and post-epidemic was calculated for the epidemic periods of 
2011/12, 2014/15 and 2015/16 (Table 2). In all cases there was a greater percentage of positive 





Table 2. Proportion of total samples positive for M. pneumoniae during the pre-epidemic, epidemic and post-epidemic periods for the three 
epidemic years of 2011/12, 2014/15 and 2015/16 for nine countries reporting both positive and negative sample data.  
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Distribution of M. pneumoniae positivity by age 
The distribution of M. pneumoniae positivity by age group was determined for each of the 12 
participating countries (Figure 3).  Even distribution across all age groups was not noted in the data 
from any country. Country specific age data revealed three distinct patterns. Four countries (Germany, 
Greece, Ireland and Slovenia) showed skewing of positive samples to younger patients (<10 y old), 
whereas two countries (Hungary and Sweden) showed skewing towards older patients (>25 y old). 
Five countries reported a bimodal distribution (Belgium, Denmark, Great Britain, France, and Israel).   
Data obtained from Norway was not sub-categorised by age. Data was not available from Ireland for 
ages 25 and above.  
Correlation between latitude and onset of epidemic period.   
When examining the epidemic period of 2011/12, 2014/15 and 2015/16, a clear association between 
the country latitude and beginning of the national epidemic period was observed (Figure 4). This was 
statistically significant for 2011/12 period (p = <0.005, r2 = 0.92) and 2014/15 (p = < 0.005, r2 = 0.84, 
but significance was not achieved during the 2015/16 period (p = 0.1, r2 = 0.38). Furthermore this 
association was most apparent during the major epidemic period of 2011/12 in which the epidemic 
period was first noted in Norway (60.4oN) during epidemic week 22 (calendar week 40 of 2011) and 
was then observed to start in Israel (31oN) during epidemic week 43 (calendar week 9 of 2012). There 












This study represents the largest data set to date of M. pneumoniae positive samples and associated 
data for which the method of M. pneumoniae detection in each country was determined.  NAATs were 
the most common method used among the twelve countries.  Although a variety of commercial and 
in-house methodologies were used in the detection of M. pneumoniae, a recent study of thirteen 
assays used across Europe, Israel and USA demonstrated comparable levels of detection of 20 M. 
pneumoniae genomes per reaction (14). Serological methods were also commonly used in the 
detection of M. pneumoniae infections.  The presence of an IgM response may have the advantage to 
suggest recent acquisition of infection, but may be an unreliable marker due to documented long term 
persistence of antibodies (15).  Culture dependent methods were used by three countries.  Culture 
has the benefit of confirming the presence of viable M. pneumoniae and may permit phenotypic 
antimicrobial susceptibility testing, but due to considerable time required for growth (up to 4 weeks) 
does not provide results within a clinically relevant time period.  Currently no single method is 
recommended for routine detection of M. pneumoniae and international guidelines or control 
materials do not exist.  Real-time PCR and serology have previously shown agreement in ability to 
detect M. pneumoniae among samples (90% agreement) with only 7% of patients being PCR positive, 
with limited evidence of seroconversion (16).  No single test can reliably detect all infections. 
Therefore a combined approach utilising both NAAT and serology may help to identify any potential 
false-negative results (17).   
In addition to method of detection, we sought to identify if surveillance for macrolide resistance was 
routinely undertaken.  Due to intrinsic resistance to many antibiotics, including all cell wall inhibitors, 
macrolide antibiotics, such as azithromycin and clarithromycin are the drug of choice or in cases of 
suspected infection among the immunocompromised, the bactericidal fluoroquinolones may be 
considered.  Tetracyclines are also used in adults for treating possible macrolide-resistant M. 
pneumoniae infections. Routine macrolide resistance monitoring was not systematically in place. This 
may attribute to the under detection of resistance, or reflect the low levels of macrolide resistance 
reported across Europe (18-20), although high levels of resistance have been noted in areas such as 
Israel (30%) (21).  However, macrolide resistance among M. pneumoniae appears to be endemic within 
countries such as China with studies routinely reporting macrolide resistance levels around 90 – 100% 
(22, 23).  This high incidence of macrolide resistance adds weight to need for co-ordinated surveillance 
across Europe, increasing clinical knowledge of macrolide resistance rates and acquisition, as well as 
an understanding of the patient’s recent travel history when considering therapy.  The authors in this 
paper, including several international experts in M. pneumoniae recommend co-ordinated 
international surveillance for macrolide resistance, as this is the current treatment of choice in Europe. 
 
 
Regardless of methodology used for detection of M. pneumoniae, clear seasonal trends were apparent 
between January 2011 and April 2016 with the peaks in infection occurring between the fourth quarter 
and first quarter of the following year. To calculate the epidemic period for each season the Moving 
Epidemic Method, as described by Vega et al., was used (12). Three clear epidemics were noted in 
2011/12, 2014/15 and 2015/16.  M. pneumoniae epidemics have been suggested to occur every 4 to 
7 years and in some cases lasting for longer than one annual season (8, 24). However, in this study 
with the largest data set so far available it was found that the interval between epidemic occurrence 
was 3 years from 2011/12 and 1 year to 2015/16. This latter epidemic period may reflect a secondary 
peak of cases within a 2 year epidemic span as previous epidemics have been shown to persist for 
some time (5, 24). Confirmation of circulating genotypes of M. pneumoniae from large geographical 
areas would be of interest to determine the microbiological nature of strains within these and 
epidemic periods.  
For the major epidemic periods, we sought to determine any changes between the pre-epidemic, 
epidemic and post-epidemic periods in the reported number of detections in countries reporting both 
positive and negative data. The greatest rise was seen in Ireland in which the 18% of samples positive 
for M. pneumoniae in the pre-epidemic period, rose by 12% percent to 30% during the epidemic 
period.  In a number of countries, such as Denmark, France, Slovenia and Sweden the prevalence in 
the post-epidemic period was lower than that of the pre-epidemic period.  This lower prevalence in 
the post-epidemic period may reflect over-sampling as a bias as a result of higher prevalence during 
the epidemic. This may also reflect an increase in the population burden of infection prior to an 
epidemic. Additional analysis is required to understand if this is the case and if monitoring of levels 
can be used to predict imminent epidemics. 
A curious observation was the pattern of positive detections stratified by age.  M. pneumoniae cases 
are classically seen among children of 5 – 14 years with those under five experiencing milder disease 
(17). This trend was seen with countries such as Germany, Greece and Slovenia which show a skew to 
the younger age groups.  For Greece this can be attributed to the acquisition of samples from a tertiary 
children’s hospital in Athens.  It should be noted that the skew to younger ages groups seen in Ireland 
may reflect the nature of only investigating patients up to the age of 25 years.  The second pattern 
observed demonstrated a peak in infection among the 5-14 years age group, with an increase in the 
25 – 44 years age group therefore giving a bimodal distribution.  Finally a skew to the older age groups 
was seen in Hungary and Sweden. This observation is not likely to be an artefact of testing 
methodology in which the elderly may be more likely to have existing IgM levels, as both countries do 
not solely rely on serology.  The reason for this increased detection in the elderly in two countries is 
 
 
unknown and may simply reflect differences in local testing guidelines and routine practice for 
respiratory screening, or merely reflect age-based screening practice such as the fact that the majority 
of Hungarian samples were derived from an elder population.  
The final analysis undertaken examined the association between the start of epidemic periods, as 
calculated by the MEM model and the geographical location of the country as determined by latitude. 
Geographical location is not thought to be of importance in progression of M. pneumoniae infection, 
but the data presented here examining the start of epidemic periods across 12 countries suggests that 
more Northerly countries experience the start of epidemic periods earlier than those in the South.  
This association was most clear during the 2011/12 epidemic period, but held true for both 
subsequent epidemic periods of 2014/15 and 2015/16.  Previous national based studies have shown 
epidemics to be polyclonal in nature (25-30). Establishment of whether the microbiological nature of 
the epidemics across Europe are clonal or not may be beneficial and influence future sentinel 
surveillance design.  The impact of climatic factors on M. pneumoniae infections has yet to be infected.   
Limitations 
A number of limitations are apparent; firstly, due to the variable reporting methods of each country 
specific case definitions were not considered and de-duplication methodologies were not imposed 
and were set at country specific level.  Overall reported testing activity or testing-incidence was very 
different between countries, and conclusions on analysis across countries must be considered with 
caution. Some countries, such as Ireland, did not provide a complete data set due to only investigating 
M. pneumoniae in patients who were 24 years and under.  Therefore the true number of positive 
individuals from this population is likely to be under estimated. Secondly, the data from some 
countries may not be fully representative of the whole nation.  For example data from Germany and 
France was obtained from a single region within each country and therefore may not be 
representative of national coverage. Thirdly, the data examining the distribution of detections 
stratified by age group, should be interpreted with a level of caution.  The age categories did not 
contain equal weighting of age groups, for example there were less age groups encompassed in the 0 
– 4 years compared with older age groups such as 25 – 44 years group.  Finally, this data did not take 
into account the subtypes of M. pneumoniae which have been described.   
 
Possible clinical impact arising from this study 
The comparative nature of this study has highlighted a number of interesting points with regards to 
trends in testing as well as epidemiology of M. pneumoniae infections.  Firstly countries may be under 
 
 
detecting cases due to limitation in age groups examined for the infection. The observation of a 
number of countries showing a skew towards older patients as well as bimodal distribution suggests 
that investigations for M. pneumoniae, although of significance in young children, should not be 
restrictive and that consistent testing guidelines are required.  It would be beneficial to have an agreed 
international case definition for infection with M. pneumoniae. 
This study also highlights the substantial lack of antimicrobial resistance testing and surveillance of M. 
pneumoniae and the potential reduced evidence base on resistance to guide therapy.  Without active 
coordinated monitoring it will not be possible to track changes in resistance profiles and the 
emergence of high-level macrolide resistant clones. There is an absence of a structured European level 
surveillance and resistance monitoring for this infection, despite the extremely high levels of 
resistance in some global areas. 
Finally the curious observation relating to association between Northern latitudes and earlier week 
initiation of epidemics may suggest the need for another more focussed study. It would also be 
interesting to assess the potential value of a rapid, real-time reporting system of M. pneumoniae 
infections across Europe.  Such a system may aid in future epidemiological studies, resistance 
monitoring, and help to predict the M. pneumoniae epidemic season throughout the continent.   
Conclusion 
This study represents the largest collection of M. pneumoniae infection data to date. There is currently 
no standardised method for the detection of M. pneumoniae infection among patients and macrolide 
resistance screening is sporadic despite high levels in some areas globally.  A wave of epidemics from 
the more northerly latitudes through to the south occurs during epidemic years, and the reason for 
this is not known. There is a need for testing guidelines and standardised international control 
material. The potential value of a co-ordinated international surveillance and macrolide resistance 
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Figure 1. Four weekly moving average data on M. pneumoniae infections across participating countries in Europe and Israel between 
January 2011 to March 2016. (a) Total number of cases from 12 participating countries, (b) confirmations determined by NAAT from 




Figure 2. Analysis of M. pneumoniae in Europe and Israel between 2011 and 2016 using the Moving Epidemic Method (MEM).  Week 
numbers represent epidemic week period (week 1 represents calendar week 19).  Green dots represent pre-epidemic period, purple 
dots represent epidemic period and yellow dots represent post-epidemic period as calculated by the MEM. (a) week 19 2011 – week 
18 2012 – identified as an epidemic year, (b) week 19 2012 – week 18 2013, (c) week 19 2013 – week 18 2014, (d) week 19 2014 – 




Figure 3. Number of M. pneumoniae cases per age group across eleven European 
countries and Israel. Age specific infection data was not available for Norway. Ireland 










Figure 4. Correlation between country latitude and epidemic week number for three epidemic periods of (a) 2011/12, (b) 
2014/15 and (c) 2015/16. Countries in which epidemic periods began prior to that predicted by the Moving Epidemic Method model 
were removed from the analysis. A statistically significant association between the week in which the country epidemic began and 
epidemic week number was seen in 2011/12 (p = < 0.005 r2 = 0.92) and 2014/15 (p= < 0.005. r2 = 0.84).  No significant association 





S1 – Exclusion and de-duplication criteria by country. This supplementary material is hosted by Eurosurveillance as supporting information alongside the 
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Country De-duplication Exclusion 
Belgium Duplicate positive tests from 1 patient in a 90-day time window were 
grouped and appear in the dataset as 1 positive test. 
The data of the sentinel network of microbiological laboratories 
include "Mycoplasma-like illness" syndromes cases confirmed by one 
of the following criteria: 
Detection of nucleic acid in a nasopharyngeal or oropharyngeal swab 
or in other deep respiratory specimens 
Detection of seroconversion of IgG or significant increase in acute 
and convalescent serum sample. 
Detection of M. pneumoniae-specific IgM antibodies. 
Cyprus Data not provided Data not provided 
Denmark At individual level only the first mycoplasma positive test result 
within a season is included. If several negative mycoplasma tests are 
available per individual, only one negative mycoplasma test is 
included/counted per week. The first time an individual test positive 
for mycoplasma all subsequent negative and positive mycoplasma 
tests are excluded 
At individual level only the first mycoplasma positive test result 
within a season is included. If several negative mycoplasma tests are 
available per individual, only one negative mycoplasma test is 
included/counted per week. The first time an individual test positive 
for mycoplasma all subsequent negative and positive mycoplasma 
tests are excluded 
France Duplicate samples from the same patient (eg. with NAAT and 




None given None given 
Great 
Britain 
Duplicate data from same patient only included if sample date >1 
year between serology samples or >3 months between NAAT 
samples 
 
Serology test results from samples other than blood, serum or plasma 
were excluded. Includes NAAT methods (coded on surveillance 
database as genomic/PCR/LCR detection) on respiratory samples or 
blood, serum or plasma only. All other methods and specimen types 
(including unknown) excluded. 
Greece None given None given 
 
 
Hungary None given None given 
Ireland None given None given 
Israel Only NAAT None 
Malta Data not provided Data not provided 
Netherlands Data not provided Data not provided 
Norway None given None given 
Poland Data not provided Data not provided 
Slovakia Data not provided Data not provided 
Slovenia Duplicate samples from the same patient was included as a single 
case 
Serology excluded 
Spain Data not provided Data not provided 
Sweden  Duplicate samples from the same patient has not been excluded. Four of the laboratories could only deliver data from 2012 (three 
labs) and 2013 (one lab) and onward. 
 
 
 
